BioSpace News Archive

Biofrontera Inc. announces that patient enrollment is now complete in the Phase 3 clinical study evaluating Ameluz -PDT in combination with the BF-RhodoLED lamp for the treatment of basal cell carcinoma (BCC).

Indaptus Therapeutics, Inc. announced completion of the first cohort of patients who received a single dose in Part 1 of its INDP-D101 trial of Decoy20 and the initiation of a new cohort following review of data by the Safety Review Committee as prescribed by the clinical trial protocol.

Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, announced that it has reached an important milestone in its clinical trial for Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections.

Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, reported financial results for the second quarter ended June 30, 2023.

Clarity Pharmaceuticals is pleased to announce the successful completion of cohort 2 and advancement to cohort 3 in the dose escalation phase of its Phase I/II theranostic trial, SECuRE, evaluating 64Cu/67Cu SAR-bisPSMA in patients with mCRPC.

August 10, 2023, in a groundbreaking development, Oricell Therapeutics Co., Ltd. has received the green light for its Investigational New Drug application of OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed or refractory multiple myeloma.

ChromaCode, Inc. announced a strategic partnership with Protean BioDiagnostics Inc., a CAP/CLIA-accredited, high-complexity laboratory specializing in developing and commercializing advanced cancer diagnostic technologies.

Virpax® Pharmaceuticals, Inc. announced that it has filed a new provisional patent application with the United States Patent and Trademark Office entitled “NSAID Formulation and Method” related to its Epoladerm™ product candidate.

SciSparc Ltd. announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1.3 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

Evoke Pharma, Inc. announced its financial results for the second quarter ended June 30, 2023, and recent corporate developments.